Articles tagged with Statins
A study of 25,000 patients with familial hypercholesterolemia found a significant lower prevalence of type 2 diabetes compared to unaffected relatives, varying by the type of gene mutation. The findings suggest decreased pancreatic LDL transport may reduce cell death and lower diabetes rates.
A new study published in Diabetologia found that statin use is associated with a 46% increased risk of developing type 2 diabetes. After adjusting for confounding factors, researchers discovered that statins decrease both insulin sensitivity and secretion, leading to an increased risk of diabetes.
Research suggests statin therapy provides greatest benefit to patients with highest genetic risk of heart attack. Genetic analysis assesses heart attack risk independently of traditional factors, identifying those at higher baseline risk who reap greater benefits from therapy. The study's findings have implications for precision medici...
A new UK-based study reveals that statin users have a lower risk of developing liver cancer compared to non-users. The study found the association was strongest among current users and those with pre-existing conditions like diabetes or liver disease.
USF scientists found that statins produce a significant reduction in cholesterol levels but have failed to substantially improve cardiovascular outcomes. The researchers argue that advocates for statins have used statistical deception to inflate their effectiveness and downplay adverse effects.
A recent study suggests that statins may not protect against Parkinson's disease, despite previous reports of a potential link. The research found no evidence that statin use lowered the risk of PD, and may even increase it over time.
High-dose atorvastatin therapy has been linked to reduced blood levels of creatinine and lower incidence of acute kidney injury in heart surgery patients. This finding comes from an analysis of 14 randomized controlled clinical trials involving 1689 patients.
A recent review of 25 clinical trials with over 47,000 participants found no significant link between statin use and changes in cognition. The study's findings contradict the US Food and Drug Agency's warning about potential cognitive adverse effects of statins.
A large international study has shown that statin treatment reduces the risk of cardiovascular disease in women, with benefits similar to those seen in men. Statins have been proven to be effective in preventing heart attacks and strokes in both sexes, especially for high-risk individuals.
The American Diabetes Association is recommending that all people with diabetes take either moderate or high doses of statins to prevent heart disease. The revised Standards of Medical Care also call for a less stringent diastolic blood pressure goal of 90 mmHg, up from 80 mmHg.
Researchers found that combining clarithromycin with certain statins increases the risk of acute kidney injury or high potassium levels, potentially leading to hospital admission. The study suggests that alternative antibiotics like azithromycin may help prevent these adverse events.
A recent study found a significant association between statin use and an increased risk of developing cataracts. However, experts emphasize that the benefits of statins in preventing cardiovascular disease outweigh the potential risks. The study's findings add to the accumulating knowledge on the statin-cataract connection.
A large study found no association between rosuvastatin statin therapy and reduced fracture risk in participants with elevated inflammatory biomarkers. Despite potential biological pathways linking cardiovascular disease and osteoporosis, the results contradict previous studies suggesting a protective effect of statins on fractures.
The American College of Cardiology and American Heart Association guidelines now recommend statin therapy for individuals with an elevated estimated risk of a heart attack or stroke in the next 10 years. A study found that 97% of adults aged 66-75 qualify for statin therapy, with 100% of men in this age group being eligible.
A study in a rural Midwestern community found that the new cholesterol guidelines substantially increased the number of individuals who qualify for a statin. The biggest driver of this increase was that a larger number of older individuals without known heart disease qualified for a statin under the new guidelines.
Adding ezetimibe to statin therapy lowered cholesterol levels and reduced cardiovascular events by 6.4% in patients following heart attack, according to the IMPROVE-IT trial. The study found that adding ezetimibe resulted in a significant reduction in cardiovascular events, including heart attacks and strokes.
Two cholesterol management guidelines agree that nearly all patients with chronic kidney disease should receive statins, but 50% of those recommended are not taking them. The study found the Pooled Cohort risk equations to be accurate among people with CKD, indicating a valid tool for estimating heart disease risk.
Researchers discovered that simvastatin inhibits the growth of uterine fibroid tumors, which are responsible for half of all hysterectomies. The study found that simvastatin impedes cell growth and induces calcium-dependent cell death mechanisms in fibroid tumor cells.
Researchers discovered that statins can reverse the learning deficits caused by Noonan syndrome, a genetic disorder affecting 1 in 2,000 people. The treatment works by reducing Ras activity, allowing brain cells to communicate properly and enabling normal learning to take place.
A recent study published in Nature Communications has identified two genomic regions associated with responses to statins, paving the way for tailored treatment plans. With over 40,000 research subjects involved, this meta-analysis demonstrates a significant impact of gene profiles on statin efficacy.
A large analysis of over 40,000 individuals has identified two new genetic variants that influence how 'bad' cholesterol levels respond to statin therapy. The study found that these genetic variants collectively account for about 5% of the variation in inter-individual response to statins.
A nationwide study will test whether treatment with a statin drug can reduce the elevated risk of cardiovascular disease in individuals infected with HIV. The REPRIEVE trial aims to investigate the preventive effects and underlying mechanisms of statin therapy in this population.
Evolocumab, a new PCSK9 inhibitor, has been shown to significantly lower LDL cholesterol levels in patients with familial hypercholesterolaemia (FH) by an average of 60% more than placebo. The treatment was well-tolerated and achieved recommended LDL cholesterol targets in over 60% of patients.
A new study found that genomic data can explain around 15% of patients' responses to cholesterol-lowering statins. The research used data from a clinical trial and identified genetic signatures associated with improved or poor responses to the medication.
A large-scale analysis found statin use associated with a 12% increased risk of type 2 diabetes over four years, as well as an average weight gain of 240g. Genetic variants linked to statin efficacy also showed smaller effects on weight and diabetes risk.
A recent study published in JAMA Neurology found that patients treated with statins after suffering a hemorrhagic stroke were more likely to survive than those who weren't. The researchers also discovered that stopping statin treatments for these patients may carry substantial risks.
A study of 3,481 patients with intracerebral hemorrhage found that inpatient statin use was associated with lower mortality rates and higher discharge rates to home or rehabilitation. The study suggests that continuing statin therapy after brain hemorrhage may be beneficial for improved outcomes.
The study found that statins promote bone growth in mice with achondroplasia symptoms by rescuing degraded cartilage and increasing chondrocyte proliferation. Statin treatment also accelerated the degradation of the FGFR3 protein, a key factor in skeletal dysplasia.
The American College of Physicians (ACP) recommends Kegel exercises, bladder training, and weight loss as effective nonsurgical treatment options for women with urinary incontinence. Generic statins are also shown to improve adherence to medication and clinical outcomes compared to brand-name drugs. Chiropractic care coupled with exerc...
Researchers found that patients taking generic statins were more likely to adhere to their medication and had a significantly lower rate of cardiovascular events and death. Generic statins were also associated with improved clinical outcomes due to lower out-of-pocket costs.
The report emphasizes the need for a more individualized approach to treating cardiovascular disease, focusing on reducing cholesterol levels to specific targets based on a patient's unique health profile. This approach includes lifestyle changes, non-lipid risk factor management, and medication tailored to the patient's needs.
A long-term study found that statin therapy initiated in childhood showed benefits on atherosclerosis progression and reduced carotid intima-media thickness. However, low-density lipoprotein levels remained high, suggesting stronger or earlier treatment may be needed.
Researchers found that statin use decreased the risk of diabetic neuropathy, retinopathy, and gangrene in individuals with diabetes. However, statin use did not affect the risk of kidney disease.
The ODYSSEY LONG TERM trial demonstrates alirocumab's efficacy in lowering LDL-C and reducing cardiovascular events. The study showed a significant reduction in major cardiovascular events and improved lipid profiles, suggesting a useful addition to statin therapy for high-risk patients.
A new study suggests rosuvastatin has an initially more favourable effect on glucose levels compared to atorvastatin in type 2 diabetes patients. This makes rosuvastatin a wiser choice, especially for those struggling to control their glucose levels.
The ODYSSEY COMBO II trial shows that alirocumab, a PCSK9 inhibitor, lowers LDL-C levels significantly more than ezetimibe when added to regular statin therapy. By week 24 and 52, alirocumab achieved 50.6% and 49.5% reductions in LDL-C, respectively.
A Yale University study found that new national guidelines can accurately prescribe statins to patients at risk for cardiovascular disease. The research shows the new guidelines produce a modest increase in patient treatment, with only 92% of those with heavy plaque being assigned to statin therapy under the new method.
A Mayo Clinic task force challenges recommendations in the updated ACC/AHA cholesterol treatment guideline, suggesting an individualized treatment approach with emphasis on lifestyle changes before prescribing statins. The task force also recommends considering additional tests to refine cardiovascular risk estimates.
A new study finds that statin use significantly reduces the risk of developing Barrett's esophagus, with the greatest effect seen in obese patients. Those with a body mass index greater than or equal to 30 had a 74 percent reduction in Barrett's esophagus odds.
A new study suggests that cholesterol-lowering statins may help people with Type 2 diabetes live longer, with a 50% increase in survival rate among those taking statins. The use of statins was the only modifiable risk factor identified to be protective against mortality.
A new study suggests that individuals who are overweight, obese, or former smokers are more likely to follow recommended statin therapy for high cholesterol. Nonadherence to prescribed medication can lead to a significant risk of cardiovascular events, with studies indicating that nonadherence rates as high as 46% have been observed.
The new ACC/AHA guidelines recommend statin therapy for people with type 2 diabetes, but experts debate its appropriateness. Robert H. Eckel supports the guidelines, while Henry Ginsberg argues they are too narrow and ignore evidence of lower LDL-C levels.
Researchers discovered a specific immune response triggered by statins that impairs insulin function, increasing the risk of diabetes. Combining statins with another medication may suppress this side effect, offering potential new targets for minimizing adverse effects.
A study found that statin users engaged in less moderate and vigorous physical activity, while having more sedentary behavior. The possible reasons for this include general muscle pain caused by statins.
A long-term study found that statin use is associated with less physical activity among older men, with an average loss of 40 minutes per week. This could decrease the medication's benefit and impact overall health, especially in those who are already frail or sedentary.
Researchers discovered that statins can alter the inflammatory response to rhinovirus, a common cause of the cold, in individuals with asthma. This finding suggests that statins may help prevent or reduce asthma symptoms resulting from colds, and could lead to further research into novel asthma control strategies.
A recent study found that discontinuing statins in patients with advanced illnesses resulted in improved overall quality of life and lower costs. Patients who stopped taking statins appeared to live slightly longer and reported better psychological wellbeing.
Despite improvements in supportive care, the mortality rate remains high due to sepsis. Statin therapy showed no significant difference in outcomes for patients with sepsis and ARDS, highlighting the need for further research into alternative treatments.
A large multicenter clinical trial led by Dr. Gerard J. Criner found that statin drugs do not reduce the number and severity of flare-ups from chronic obstructive pulmonary disease (COPD). The study tested the hypothesis that statins may be beneficial in persons with COPD due to their anti-inflammatory effect.
A phase 3 study found that evolocumab, a human monoclonal antibody, added to moderate- or high-intensity statin therapy further lowers LDL-C levels by up to 24 percent. The treatment was well-tolerated and showed similar results across different statin types and doses.
Researchers found an estimated 9 million people with diabetes and 5.6 million people with coronary artery disease are not receiving statins, highlighting a concerning trend driven by high cholesterol. Statin use is often associated with reduced cardiovascular risk, regardless of cholesterol levels.
Researchers found that combining EPA with statins reversed endothelial damage more effectively than statins alone. The combination showed a potent interaction in reducing cardiovascular risk.
A recent study found that statin therapy lowers LDL cholesterol and reduces the risk of heart disease and stroke in patients with chronic kidney disease, but has no effect on kidney function or progression. The Study of Heart and Renal Protection (SHARP) included 6,245 patients who received a placebo or cholesterol-lowering treatment w...
Studies by Penn neurologists investigate the potential of statin use and estrogen to delay Parkinson's onset, with promising findings. Telemedicine is also shown to improve access to specialty care for patients with Parkinson's disease.
A new UCLA-led study suggests that people taking statins in the 2009-10 year consumed more calories and fat than those who used statins 10 years earlier. Researchers found a significant increase in caloric intake among statin users, with no similar change among non-statin users.
A new Rutgers study suggests that statin medication can not only lower cholesterol and reduce the risk of heart attack and stroke but also improve a man's erectile function. The researchers found that older men with poor cardiovascular health, diabetes, or metabolic syndrome often experience erectile dysfunction.
The LAPLACE-2 study shows evolocumab produces highly significant reductions in LDL cholesterol when added to statins, with 93% of patients achieving an LDL level below 70mg/dL. Evolocumab also reduces non-HDL cholesterol, apolipoprotein B and lipoprotein (a) levels without liver damage or muscle problems.
In a phase III study, evolocumab was shown to effectively lower LDL-C levels, with fewer side effects compared to ezetimibe. The results suggest that evolocumab may be a promising alternative for patients who cannot tolerate statins due to intolerable side effects.
A study comparing US and European cholesterol guidelines found substantial differences in statin use recommendations for men and women. The application of these guidelines to a European population resulted in varying proportions of individuals eligible for statins.
A new analysis found that using risk equations can help guide statin therapy for heart disease patients, suggesting they are helpful for clinical decision making. The study also suggests the Pooled Cohort risk equations are valid for informing clinical management decisions.